Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 25, 2012

View Archived Issues

Phase II VTX-2337 trial in persistent ovarian cancer begins

Roche reviews highlights of third quarter 2012

Phase III MM-003 study meets primary endpoint

Study finds genetic variants associated with response to cocaine vaccine

Calcium-activated potassium channel expression investigated in Parkinson's disease model

Novel antibacterial thiolactomycin analogues presented

Chinese researchers disclose new agents for cancer

Bayer Schering Pharma prepares novel TTK inhibitors

New c-Cot inhibitors patented by Glenmark Pharmaceuticals

Researchers at Amgen patent novel protein kinase inhibitors

Duke University presents novel oligopeptides for inflammation and neurological conditions

Urine MIF could be a useful biomarker of interstitial cystitis

Astex Pharmaceuticals begins phase II study of its HSP 90 inhibitor

Seattle Genetics and Abbott expand antibody-drug conjugate collaboration

FDA accepts NDA filing for ponatinib

4SC Discovery receives research grant to develop personalized cancer drugs

Agenus begins phase II study of HerpV vaccine

Compound-loaded artificial bone acts on host cells to induce regeneration

Phase III trial of ALK-Abello's allergy vaccine meets primary endpoint

Investigator-sponsored trial of Cytori's cell therapy for scleroderma cleared in France

Xalkori granted conditional approval in Europe

Ataluren benefits selected patients with cystic fibrosis in phase III trial

EMA accepts for review lurasidone MAA

Phase III trial of reparixin in pancreatic islet transplantation enrolls first patient

Oryzon receives grant from Spanish government to develop LSD1 inhibitors for acute leukemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs
BioWorld Science
Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...